These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16373705)

  • 21. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
    Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
    Ahn K; O YM; Ji YG; Cho HJ; Lee DH
    Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton.
    Kilarski WW; Jura N; Gerwins P
    Exp Cell Res; 2003 Nov; 291(1):70-82. PubMed ID: 14597409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autocrine VEGF and IL-8 Promote Migration via Src/Vav2/Rac1/PAK1 Signaling in Human Umbilical Vein Endothelial Cells.
    Ju L; Zhou Z; Jiang B; Lou Y; Guo X
    Cell Physiol Biochem; 2017; 41(4):1346-1359. PubMed ID: 28278510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells.
    Abu-Ghazaleh R; Kabir J; Jia H; Lobo M; Zachary I
    Biochem J; 2001 Nov; 360(Pt 1):255-64. PubMed ID: 11696015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
    Azuma K; Kawahara A; Hattori S; Taira T; Tsurutani J; Watari K; Shibata T; Murakami Y; Takamori S; Ono M; Izumi H; Kage M; Yanagawa T; Nakagawa K; Hoshino T; Kuwano M
    J Thorac Oncol; 2012 May; 7(5):779-89. PubMed ID: 22481237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation.
    Li MH; Miao ZH; Tan WF; Yue JM; Zhang C; Lin LP; Zhang XW; Ding J
    Clin Cancer Res; 2004 Dec; 10(24):8266-74. PubMed ID: 15623602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the CXCR4 signaling in pancreatic cancer cells.
    Billadeau DD; Chatterjee S; Bramati P; Sreekumar R; Shah V; Hedin K; Urrutia R
    Int J Gastrointest Cancer; 2006; 37(4):110-9. PubMed ID: 18175225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.
    Koul D; Shen R; Bergh S; Lu Y; de Groot JF; Liu TJ; Mills GB; Yung WK
    Mol Cancer Ther; 2005 Nov; 4(11):1681-8. PubMed ID: 16275989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
    Halder SK; Beauchamp RD; Datta PK
    Neoplasia; 2005 May; 7(5):509-21. PubMed ID: 15967103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.
    Dhanabal M; Wu F; Alvarez E; McQueeney KD; Jeffers M; MacDougall J; Boldog FL; Hackett C; Shenoy S; Khramtsov N; Weiner J; Lichenstein HS; LaRochelle WJ
    Cancer Biol Ther; 2005 Jun; 4(6):659-68. PubMed ID: 15917651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.
    Delle Monache S; Sanità P; Calgani A; Schenone S; Botta L; Angelucci A
    Exp Cell Res; 2014 Oct; 328(1):20-31. PubMed ID: 25128812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.
    Park SI; Shah AN; Zhang J; Gallick GE
    Expert Opin Ther Targets; 2007 Sep; 11(9):1207-17. PubMed ID: 17845146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.